NCT07517211Not yet recruiting
A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer, FAST-GO Study
A Prospective Study of Physical Function in Adults Who Receive Systemic Therapy for Stage I-III Gastroesophageal Cancer (FAST-GO)
Source: ClinicalTrials.gov · Last updated 7 Jul 2026
Brief summary (registry, in English)
This study evaluates how the treatment for gastroesophageal cancer affects physical function in patients who receive chemotherapy as part of their treatment for gastroesophageal cancer.
- Status (registry)
- Not yet recruiting
- Study type
- Observational
- Enrollment
- 72 (estimated)
- First submitted
- 30 Mar 2026
- Start date
- 1 Dec 2026
- Primary completion date
- 1 Dec 2029
- Lead sponsor
- Jonsson Comprehensive Cancer Center
- Diseases
- Gastric and esophageal cancer
- NCT number
- NCT07517211
What you commit to
- Study type: Observational
- Planned participants: 72
- From 1 Dec 2026 to the primary completion date, 1 Dec 2029
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- \* Patients with stage I disease with plans to undergo endoscopic resection or surgery alone without perioperative systemic therapy.
- Metastatic disease at the time of diagnosis.
- Patients who are unable to provide informed consent.
- Any condition that would, in the Investigator's judgment, contraindicate the patient's participation in the clinical study due to safety concerns with clinical study procedures.
- Currently participating in another intervention research study seeking to improve functional status, alleviate frailty, increase muscle strength, or improve cognitive function.
Who the study is looking for
- \* Adults ≥ 18 years old at the start of study treatment.
- New diagnosis of early-stage (Stage I, II, III) esophageal, gastroesophageal junction, or gastric adenocarcinoma, squamous cell carcinoma, or poorly differentiated carcinoma.
- Plan to start systemic therapy for resectable or potentially resectable disease.
- Ability to understand and the willingness to sign a written informed consent document.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| UCLA / Jonsson Comprehensive Cancer Center Coordinator of this site? Confirm its status | Los Angeles | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.